Enhanced Nutritional Optimization in LVAD Trial

Heart Failure Clinical Trial

— ENOL  

Official title:

Enhanced Nutritional Optimization in LVAD (ENOL) Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05655910
• Other study ID #: AAAT9591
• Status: Recruiting
• Phase: N/A
• Start date: September 22, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: November 2022
• Source: Columbia University
• Contact: Melana Yuzefpolskaya, MD
• Phone: 3472681454
• Email: my2249[@]cumc.columbia.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to assess whether a peri-operative intervention with nutritional immune modulating intervention (Ensure Surgery Immunonutrition shake) has beneficial effects on the complex interplay between gut microbiome, systemic inflammation and malnutrition that is commonly present in advanced heart failure and the adverse events associated with left ventricular assist device (LVAD) placement in hospitalized advanced heart failure patients awaiting LVAD implantation. The main questions it aims to answer are: - Will pre-surgical supplementation with Ensure Surgery affect gut microbial composition and levels of inflammation among heart failure patients undergoing LVAD implantation? - Will pre-surgical supplementation with Ensure Surgery affect post-surgical morbidity (e.g., infections, intensive care unit length of stay (LOS)) and mortality? Participants will be evaluated for malnutrition and will be given Ensure Surgery Immunonutrition shake to drink in the days preceding their LVAD surgery. Blood and stool samples will be collected at prespecified timepoints before and after surgery. Researchers will compare malnourished participants drinking Ensure Surgery 3/day with well-nourished participants randomized to drink either 1/day or 3/day to see if any of the above supplementation strategies change the gut microbial composition, levels of inflammation, and post-surgical morbidity and mortality.

Description:

Heart failure (HF) has an estimated prevalence of >37.7 million individuals globally. In the US alone, which is projected to increase by 46% between the years 2012 and 2030. Despite significant advances in HF medical and device therapies, patient prognosis after their first HF hospital admission is poor, with a <50% survival rate at five years and significant proportion of patients progressing from chronic stable disease to advanced HF state. Once advanced HF ensues, LVADs are one of the two main treatment modalities that can meaningfully improve survival in this patient population. Chronic systemic inflammation is commonly observed in HF and is believed to be directly related to its pathogenesis. Recently, perturbations in the gut microbiota known as "gut dysbiosis" and impairment of gut mucosal barriers, facilitating entry of endotoxins and gut metabolites into the circulation, have also been observed in HF patients. Elevated levels of circulating endotoxins and bacterial bi-products enhance systemic inflammation, thereby contributing to progression of HF to more advanced disease state. Gut microbial perturbations may also alter enterocyte structure and function resulting in gastrointestinal dysmotility, nutrient malabsorption and eventually malnutrition. Malnutrition is frequent in HF (as high as 62%), is associated with higher rates of mortality, hospital readmissions and an increased risk of adverse early postoperative outcomes. Infections are the most common complications following LVAD, affecting >50% of HF patients, contributing significantly to postoperative mortality, increased length-of stay (LOS) and hospital readmissions. The pre-operative period may represent an attractive time window in which to optimize HF patients, correct deficiencies, and enhance immune defense mechanisms before surgery. This period allows to act upon modifiable risk factors, such as the nutritional status, and potentially lower the risk of postoperative complications. However, the literature on perioperative optimization in HF comes mainly from anesthesiology and focuses on intra- and immediate postoperative management, when it may be too late to intervene and alter the outcome. Interestingly, guidelines on the nutritional evaluation and management of patients prior to non-cardiac surgery are available, but very limited literature is published concerning cardiac surgery, and no data exists with respect to LVAD surgery. The investigators plan to evaluation of the impact of preoperative nutrition intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age >18 years
• hospitalized
• undergoing LVAD therapy (enrolled at time of acceptance)

Exclusion Criteria:

• intubated
• congenital heart disease
• infiltrative cardiomyopathy
• unable to tolerate oral nutrition
• surgery expected in <5 days

Related Conditions & MeSH terms

• Gut Microbiome
• Heart Failure
• Malnutrition
• Nutritional Deficiency

Intervention

Dietary Supplement:
• Ensure Surgery Immunonutrition shake
Nutrition shake to support immune health and recovery from surgery.

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Columbia University	Abbott Nutrition

Country where clinical trial is conducted

United States, 

References & Publications (15)

Al-Najjar Y, Clark AL. Predicting outcome in patients with left ventricular systolic chronic heart failure using a nutritional risk index. Am J Cardiol. 2012 May 1;109(9):1315-20. doi: 10.1016/j.amjcard.2011.12.026. Epub 2012 Feb 13. — View Citation

Engelman DT, Ben Ali W, Williams JB, Perrault LP, Reddy VS, Arora RC, Roselli EE, Khoynezhad A, Gerdisch M, Levy JH, Lobdell K, Fletcher N, Kirsch M, Nelson G, Engelman RM, Gregory AJ, Boyle EM. Guidelines for Perioperative Care in Cardiac Surgery: Enhanced Recovery After Surgery Society Recommendations. JAMA Surg. 2019 Aug 1;154(8):755-766. doi: 10.1001/jamasurg.2019.1153. — View Citation

Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990 Nov;82(5):1724-9. doi: 10.1161/01.cir.82.5.1724. — View Citation

Gustafsson UO, Scott MJ, Schwenk W, Demartines N, Roulin D, Francis N, McNaught CE, MacFie J, Liberman AS, Soop M, Hill A, Kennedy RH, Lobo DN, Fearon K, Ljungqvist O; Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr. 2012 Dec;31(6):783-800. doi: 10.1016/j.clnu.2012.08.013. Epub 2012 Sep 28. — View Citation

Kummen M, Mayerhofer CCK, Vestad B, Broch K, Awoyemi A, Storm-Larsen C, Ueland T, Yndestad A, Hov JR, Troseid M. Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. J Am Coll Cardiol. 2018 Mar 13;71(10):1184-1186. doi: 10.1016/j.jacc.2017.12.057. No abstract available. — View Citation

Lin H, Zhang H, Lin Z, Li X, Kong X, Sun G. Review of nutritional screening and assessment tools and clinical outcomes in heart failure. Heart Fail Rev. 2016 Sep;21(5):549-65. doi: 10.1007/s10741-016-9540-0. — View Citation

Luedde M, Winkler T, Heinsen FA, Ruhlemann MC, Spehlmann ME, Bajrovic A, Lieb W, Franke A, Ott SJ, Frey N. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail. 2017 Aug;4(3):282-290. doi: 10.1002/ehf2.12155. Epub 2017 Apr 21. — View Citation

Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1996 Apr 1;77(9):723-7. doi: 10.1016/s0002-9149(97)89206-5. — View Citation

Roger VL. Epidemiology of heart failure. Circ Res. 2013 Aug 30;113(6):646-59. doi: 10.1161/CIRCRESAHA.113.300268. — View Citation

Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007 Oct 16;50(16):1561-9. doi: 10.1016/j.jacc.2007.07.016. Epub 2007 Oct 1. — View Citation

Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2. — View Citation

Schorghuber M, Fruhwald S. Effects of enteral nutrition on gastrointestinal function in patients who are critically ill. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):281-287. doi: 10.1016/S2468-1253(18)30036-0. Epub 2018 Mar 7. — View Citation

Sze S, Zhang J, Pellicori P, Morgan D, Hoye A, Clark AL. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction. Clin Res Cardiol. 2017 Jul;106(7):533-541. doi: 10.1007/s00392-017-1082-5. Epub 2017 Feb 15. — View Citation

Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, LeJemtel TH. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996 Oct;28(4):964-71. doi: 10.1016/s0735-1097(96)00268-9. — View Citation

Yuzefpolskaya M, Bohn B, Nasiri M, Zuver AM, Onat DD, Royzman EA, Nwokocha J, Mabasa M, Pinsino A, Brunjes D, Gaudig A, Clemons A, Trinh P, Stump S, Giddins MJ, Topkara VK, Garan AR, Takeda K, Takayama H, Naka Y, Farr MA, Nandakumar R, Uhlemann AC, Colombo PC, Demmer RT. Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. J Heart Lung Transplant. 2020 Sep;39(9):880-890. doi: 10.1016/j.healun.2020.02.004. Epub 2020 Feb 13. — View Citation

* Note: There are 15 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Alpha Diversity (Baseline and Day 5)	Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples.	Baseline and Day 5
Primary	Change in Alpha Diversity (Baseline and Pre-VAD)	Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Alpha Diversity (Baseline and Discharge)	Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Alpha Diversity (Baseline and Post-Discharge Follow-up)	Change in alpha diversity (a measure of microbiome diversity applicable to a single sample) in collected stool samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in Microbial Gene Count (Baseline and Day 5)	Change in microbial gene count as measured in stool samples.	Baseline and Day 5
Primary	Change in Microbial Gene Count (Baseline and Pre-VAD)	Change in microbial gene count as measured in stool samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Microbial Gene Count (Baseline and Discharge)	Change in microbial gene count as measured in stool samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Microbial Gene Count (Baseline and Post-Discharge Follow-up)	Change in microbial gene count as measured in stool samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in C-Reactive Protein (CRP) (Baseline and Day 5)	Change in biomarker CRP as measured in blood samples.	Baseline and Day 5
Primary	Change in C-Reactive Protein (CRP) (Baseline and Pre-VAD)	Change in biomarker CRP as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in C-Reactive Protein (CRP) (Baseline and Discharge)	Change in biomarker CRP as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in C-Reactive Protein (CRP) (Baseline and Post-Discharge Follow-up)	Change in biomarker CRP as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Day 5)	Change in biomarker NT-proBNP as measured in blood samples.	Baseline and Day 5
Primary	Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Pre-VAD)	Change in biomarker NT-proBNP as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Discharge)	Change in biomarker NT-proBNP as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in N-terminal (NT)-pro hormone BNP (NT-proBNP) (Baseline and Post-Discharge Follow-up)	Change in biomarker NT-proBNP as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in lipopolysaccharide (LPS) (Baseline and Day 5)	Change in biomarker LPS as measured in blood samples.	Baseline and Day 5
Primary	Change in lipopolysaccharide (LPS) (Baseline and Pre-VAD)	Change in biomarker LPS as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in lipopolysaccharide (LPS) (Baseline and Discharge)	Change in biomarker LPS as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in lipopolysaccharide (LPS) (Baseline and Post-Discharge Follow-up)	Change in biomarker LPS as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in Tumor Necrosis Factor (TNF) (Baseline and Day 5)	Change in biomarker TNF as measured in blood samples.	Baseline and Day 5
Primary	Change in Tumor Necrosis Factor (TNF) (Baseline and Pre-VAD)	Change in biomarker TNF as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Tumor Necrosis Factor (TNF) (Baseline and Discharge)	Change in biomarker TNF as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Tumor Necrosis Factor (TNF) (Baseline and Post-Discharge Follow-up)	Change in biomarker TNF as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in Interleukin 6 (IL-6) (Baseline and Day 5)	Change in biomarker IL-6 as measured in blood samples.	Baseline and Day 5
Primary	Change in Interleukin 6 (IL-6) (Baseline and Pre-VAD)	Change in biomarker IL-6 as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Interleukin 6 (IL-6) (Baseline and Discharge)	Change in biomarker IL-6 as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Interleukin 6 (IL-6) (Baseline and Post-Discharge Follow-up)	Change in biomarker IL-6 as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in Interleukin 10 (IL-10) (Baseline and Day 5)	Change in biomarker IL-10 as measured in blood samples.	Baseline and Day 5
Primary	Change in Interleukin 10 (IL-10) (Baseline and Pre-VAD)	Change in biomarker IL-10 as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Interleukin 10 (IL-10) (Baseline and Discharge)	Change in biomarker IL-10 as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Interleukin 10 (IL-10) (Baseline and Post-Discharge Follow-up)	Change in biomarker IL-10 as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Primary	Change in Short-Chain Fatty Acids (Baseline and Day 5)	Change in short-chain fatty acids as measured in blood samples.	Baseline and Day 5
Primary	Change in Short-Chain Fatty Acids (Baseline and Pre-VAD)	Change in short-chain fatty acids as measured in blood samples.	Baseline and Pre-VAD (approximately Day 0-5)
Primary	Change in Short-Chain Fatty Acids (Baseline and Discharge)	Change in short-chain fatty acids as measured in blood samples.	Baseline and Discharge (approximately Day 25)
Primary	Change in Short-Chain Fatty Acids (Baseline and Post-Discharge Follow-up)	Change in short-chain fatty acids as measured in blood samples.	Baseline and Post-Discharge Follow-up (approximately Day 55)
Secondary	Post-LVAD Infections	Number and type of infections experienced during index hospitalization following LVAD implantation	Day 25
Secondary	Post-LVAD Length of Stay in intensive care unit	Number of days spent in intensive care unit following LVAD implantation.	Day 25
Secondary	Post-LVAD Mortality	Number of participant deaths.	Up to 2 years